Thank you for a successful ILC 2021!
Thank you for making the 2021 International Invasive Lobular Breast Cancer (ILC) Virtual Symposium a success. Over 740 physicians, researchers, patient advocates, patients with ILC from 36 countries participated to learn about ILC and discuss the most current research underway to better understand this unique disease.
The ILC Virtual Symposium was held June 24th-25th, 2021 with special ILC patient advocate focused sessions June 23rd and June 30th. The Symposium showcased rapid progress in lobular breast cancer research with an agenda that featured presentations and discussions tackling challenges and opportunities that are ongoing in ILC diagnostics, imaging, biology and treatment and the growth of patient advocacy organizations ready to support the research.
Speakers, supporting organizations, patient advocates and symposium participants shared enthusiasm to build international, collaborative research to better understand ILC and develop therapies for patients. We look forward to following this symposium with concrete steps to build the essential tools for ILC research and launch the studies and trials that are needed to benefit patients. We welcome your involvement moving forward.
Thank you to presenters and to our Symposium Sponsor, the Breast Cancer Research Foundation and our supporting organizations Susan G Komen, the European Lobular Breast Cancer Consortium, the Lobular Breast Cancer Alliance, Lobular Breast Cancer UK, Lobular Ireland and the Dynami Foundation whose support made this event possible. Thank you to the patients, survivors, patient advocates and breast cancer organizations who are a crucial part of research community in the fight against lobular breast cancer.
For those who missed the scientific or patient advocate focused sessions, recordings of presentations will become available over the next 1-2 weeks to watch and share.
We hope that the symposium sparked fresh ideas, inspiration, and new collaborations. We appreciate your attendance and participation, and we look forward to meeting again at an in-person Symposium in Europe in 2022.
Best Regards,
Virtual ILC Symposium Organizers
Watch the recorded sessions below
Thank you to the presenters who agreed to record and share their presentations. Not all presentations were recorded. Please contact the presenters directly with questions.
ILC 2021 – Patient Advocate Orientation, June 23rd, 2021
Basic tools and information for patients and advocates to make the most of the scientific sessions of the International ILC Virtual Symposium and learn about lobular breast cancer.
ILC 2021 – Scientific Sessions Day 1 – Morning, June 24th, 2021
Keynote Address: Christine Desmedt
Session 1: Addressing Challenges in Diagnosis, Pathology and Imaging
ILC 2021 – Scientific Sessions Day 1 – Afternoon, June 24th, 2021
Session 2: Addressing Challenges in ILC Treatment
ILC 2021 – Scientific Sessions Day 2 – Morning, June 25th, 2021
Panel Discussion: How researchers, clinicians and patient advocates can accelerate lobular breast cancer research
Session 1: New Avenues in ILC Research
ILC 2021 – Scientific Sessions Day 2 – Afternoon, June 25th, 2021
Session 2: Lobular Breast Cancer Biology
ILC 2021 – Symposium Highlights – June 30th, 2021
Highlights of the International ILC Virtual Symposium
Welcome to ILC 2021!
We are delighted to invite you to the International Invasive Lobular Breast Cancer (ILC) Virtual Symposium to be held virtually on June 24th-25th, 2021, with special patient advocate focused sessions June 23rd and June 30th.
Registration is free and open to physicians, researchers, patient advocates and organizations interested in learning about ILC and the most current research to better understand this disease. This virtual symposium replaces the 2020 symposium, canceled due to the pandemic.
We believe that this symposium will be an opportunity to share current research in ILC and continue to build a vibrant, collaborative community of physicians, researchers, and advocates, ultimately impacting outcomes for patients with ILC. We encourage you to participate in these discussions and to voice your ideas and suggestions as we plan future projects.
We take this opportunity to thank the patients, survivors, patient advocates and breast cancer organizations who are a crucial part of research community in the fight against lobular breast cancer. We hope that after the symposium you take away fresh ideas, inspiration, and new collaborations. We appreciate your attendance and participation in this symposium and we look forward to meeting again at an in-person Symposium in Europe in 2022.
Best Regards,
Steffi Oesterreich, PhD
Professor, Pharmacology & Chemical Biology, University of Pittsburgh
Co-Director of the Women’s Cancer Research Center
Co-Leader, Cancer Biology Program, UPMC Hillman Cancer Center
Magee-Womens Research Institute, Pittsburgh, PA
Co-Chair, International ILC Virtual Symposium
Otto Metzger, MD
Medical Oncologist, Dana-Farber Cancer Institute
Executive Officer, Alliance for Clinical Trials in Oncology
Harvard Medical School, Boston, MA
Co-Chair, International ILC Virtual Symposium
Christine Desmedt, PhD
Head of Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
Co-Chair, International ILC Virtual Symposium
Patrick W.B. Derksen, PhD
Professor, University Medical Center (UMC) Utrecht, Utrecht, Netherlands
Co-Chair, International ILC Virtual Symposium
Agenda
June 23rd – Patient Advocate Orientation
Basic tools and information for patients and advocates to make the most of the scientific sessions of the International ILC Virtual Symposium and learn about lobular breast cancer. Everyone is welcome to attend.
12:00 – 1:30pm EST
Moderator: Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Lobular Breast Cancer Consortium (ELBCC)
Karen Van Baelen, MD, KU Leuven, UZ Leuven, Leuven, Belgium: “Lobular Breast Cancer: from diagnosis to treatment”
Christine Desmedt, PhD, KU Leuven, Leuven, Belgium : “The ABCs of Cancer Biology”
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA: “Peculiarities of Lobular Breast Cancer Biology”
June 24th – Day 1 of the International ILC Virtual Symposium Scientific Sessions
Keynote Address
Christine Desmedt, PhD, Katholieke Universiteit, Leuven
“Molecular features of lobular breast cancer: opportunities for individualizing therapy“
9:00am – 10:00am EST
Presentations and Q&A: Addressing Challenges in ILC Pathology, Diagnosis and Imaging
Chair: Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
10:00am – 12:00pm EST
10:00am
Matthias Christgen, MD, Medizinische Hochschule Hannover, Hannover, Germany
“Lobular Breast Cancer: Histomorphology and different concepts of a special spectrum of tumors“
10:30am
Peter Simpson, PhD, University of Queensland, Australia
“Developing Lobsig – a signature capturing the molecular heterogeneity of ILC“
11:00am
Jorge Reis-Filho, MD, Memorial Sloan Kettering Cancer Center, NYC
“Artificial intelligence in breast pathology: beyond cancer detection“
11:30am
Hannah Linden, MD, Seattle Cancer Alliance, Seattle, WA
“Imaging challenges in ILC and molecular imaging advances“
Break
12:00pm – 12:30pm
Presentations and Q&A: Addressing Challenges in ILC Treatment
Chair: Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School. Boston, MA
12:30pm – 2:30pm EST
12:30pm
Sabine Linn, MD, PhD, Netherlands Cancer Institute, Netherlands
“Treatment of early-stage ILC. What is different?“
1:00pm
Rinath Jeselsohn, MD, Dana Farber-Cancer Institute, Boston, MA
“Estrogen signaling – what are the differences between lobular and ductal cancer?“
1:30pm
Ron Bose, MD, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
“Targeted anti-HER2 based therapy? Her2 mutations and treatment rationale“
2:00pm
Otto Metzger, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
“Discussion with breast cancer advocates on current and future aspect of ILC tailored therapies“
June 25th – Day 2 of the International ILC Virtual Symposium Scientific Sessions
Panel Discussion with Q&A: How researchers, clinicians and patient advocates can accelerate lobular breast cancer research
Leigh Pate, Founder Lobular Breast Cancer Alliance
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee Womens Research Institute, University of Pittsburgh, Pittsburgh, PA
Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance
Siobhán Freeney, Founding member Lobular Ireland; Patient Advocate, European Breast Cancer Consortium (ELBCC)
Claire Turner, Founder and Chair, Lobular Breast Cancer UK, UK Patient Advocate Representative for European Lobular Breast Cancer Consortium
9:00am – 10:00am EST
Presentations and Q&A: New Avenues in ILC Research
Chair: Patrick Derksen, PhD, UMC Utrecht (Universitair Medisch Centrum Utrecht), The Netherland
10:00am – 12:00pm EST
10:00am
Matthew Sikora, PhD, University of Colorado Cancer Center, Aurora, CO
“Understanding ILC as a unique context for interaction between estrogen signaling and DNA damage response“
10:40am
George Sflomos, PhD, Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland
“Novel Models of Lobular Breast Cancers: what we have learned and where we are heading“
11:20am
Yeji An, University of Toronto, Toronto, Canada
“Refining the ILC mouse model: exploring the role of 16q hemizygosity in breast cancer“
Break
12:00pm – 12:30pm
Presentations and Q&A: Lobular Breast Cancer Biology
Chair: Christine Desmedt, PhD, Katholieke Universiteit, Leuven
12:30pm – 2:00pm EST
12:30pm
Val Brunton, PhD, Cancer Research UK Edinburgh Centre, Edinburgh
“Tumor-stromal interactions in ILC“
1:00pm
Adrian Lee, PhD, UPMC Hillman Cancer, Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA
“Single-Cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells“
1:30pm
Patrick Derksen, PhD, UMC Utrecht, The Netherland
“Oncogene addiction 2.0. E-cadherin loss causes vulnerabilities to targeted treatments“
2:00pm
Clare Isacke, PhD, The Institute of Cancer Research, London
“Characterization and modeling of lobular breast cancer leptomeningeal metastasis“
June 30th – Highlights of the International ILC Virtual Symposium
Join leading lobular breast cancer researchers and ILC advocates for a discussion of the highlights of the International ILC Virtual Symposium and Q&A. The highlights session is open to everyone, but is tailored for patients and patient advocates.
12:00 – 1:30pm EST
Moderator: Laurie Hutcheson, Executive Director, Lobular Breast Cancer Alliance
Rachel C. Jankowitz, MD, Associate Professor of Clinical Medicine in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and Director of the Rena Rowan Breast Center at the Penn Abramson Cancer Center
Matthew J. Sikora, PhD, Assistant Professor of Pathology at the University of Colorado Anschutz Medical Campus
Gary A. Ulaner, MD, PhD, Chair of Molecular Imaging and Therapy at Hoag Family Cancer Institute
Organizing Committee
Thanks to everyone who has organized and contributed to the 2020 and 2021 International Lobular Breast Cancer Symposium
Co-Chairs:
Steffi Oesterreich, PhD, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA, USA
Otto Metzger, MD, DFCI & Women’s Cancer Center, Boston, MA, USA
Patrick W. B. Derksen, PhD, University Medical Center, Utrecht, Netherlands
Christine Desmedt, PhD, KU Leuven, Belgium
Symposium Director:
Jagmohan Hooda, PhD, University of Pittsburgh Cancer Institute, UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Scientific Organizing Committee:
Nancy E. Davidson, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Karen DiVito, Patient Advocate Leader, bcRAN
Siobhan Freeney, Patient Advocate Leader, Lobular Ireland
Laurie Hutcheson, Patient Advocate Leader LBCA
Rachel C. Jankowitz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA
Christopher I. Li, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Rita Mukhtar, MD, University of California, San Francisco, CA, USA
Leigh Pate, Patient Advocate Leader, LBCA
Lori Petitti, Patient Advocate Leader, LBCA
Matthew J. Sikora, PhD, University of Colorado Anschutz Medical Campus, Denver, CO, USA
Christos Sotiriou, MD, Institut Jules Bordet, Brussels, Belgium
Claire Turner, Patient Advocate Leader, LBCUK
Gary Ulaner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Event Organizing Committee:
Renee Mandell, Event Coordinator, Magee-Womens Research Institute , Pittsburgh, PA, USA
Nadine Ryan, Event Coordinator, Magee-Womens Research Institute , Pittsburgh, PA, USA
Daniel D. Brown, PhD, Website and Graphic Design, Laughing Mantis Studio; Research Scientist, Institute for Precision Medicine, Pittsburgh, PA
Sponsors
Supporters
